Sage Dalzanemdor Drug for Huntington’s Disease

Over the next few months, I will report on five positive clinical trials being conducted around the world for Huntington’s disease (HD)who’s drug could potentially hold the key to a higher quality of life for HD patients/families.

“The stormy trial updates that hung over the Huntington’s disease field in 2021 have certainly parted, making way for the bright and clear forecast we’ve had so far in 2024!” Dr. Rachel Harding.

Today let’s talk about the drug from Sage Therapeutics (https://en.hdbuzz.net/369) dalzanemdor

“Sage has been working on an experimental therapy called dalzanemdor. The drug acts on NMDA receptors, which help to transmit chemical messages between nerve cells. There is an imbalance in this messenger system across many diseases, which causes changes in thinking and memory. Dalzanemdor is a type of drug designed to boost the messages passed by NMDA receptors – it’s a bit like giving your brain cells a megaphone.”

“Overall, Sage’s recent press release about the SURVEYOR trial suggests dalzanemdor is generally safe. And perhaps more importantly, it suggests we have a robust way to measure cognition in HD with the HD-CAB. ”